CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both important.

Research output: Contribution to journal › Editorial

Cite this

@article{37965165d1db4147a8534391bce273ea,

title = "CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both important.",

author = "Holtzman, {David M.}",

year = "2012",

month = jun,

language = "English",

volume = "69",

pages = "691--692",

journal = "Archives of Neurology",

issn = "0003-9942",

number = "6",

}

TY - JOUR

T1 - CSF biomarkers for secondary prevention trials

T2 - why markers of amyloid deposition and neurodegeneration are both important.

AU - Holtzman, David M.

PY - 2012/6

Y1 - 2012/6

UR - http://www.scopus.com/inward/record.url?scp=84865603192&partnerID=8YFLogxK

M3 - Editorial

C2 - 22529246

AN - SCOPUS:84865603192

VL - 69

SP - 691

EP - 692

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 6

ER -